News | March 09, 2024
Jagsonpal Pharmaceuticals launches QueeZy-ER
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
ANVISA issues CGMP to Concord Biotech’s Unit I
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Cipla completes transfer of Generics Business Undertaking
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
